Clinicians should be reassured that patients with obesity and on antidepressants who don t have major depressive disorder or suicidality in the past 2 years can receive semaglutide, says a researcher.
Unlike tirzepatide, which combines weight loss and glucose-lowering properties, this twincretin reduces liver fat along with weight, blood pressure, and lipid levels.